Aug 16, 2018 | Featured Insights
Last week, Baron & Budd’s lawyers secured $90 million from AstraZeneca in a resolution that the pharmaceutical company targeted the Texas Medicaid system with a fraudulent marketing scheme for its expensive and powerful atypical antipsychotic drugs Seroquel IR and... 
Aug 14, 2018 | Featured Insights
A notable settlement with big pharma was reached last week. Joel M. Androphy and Sarah M. Frazier of Berg & Androphy, along with the State of Texas and other law firms, reached settlements in Texas Medicaid Fraud Prevention Act litigation against AstraZeneca. This... 
Aug 8, 2018 | Featured Insights
Last week, Dallas-based Baron & Budd secured a major settlement with Endo Pharmaceuticals Inc. (“Endo”), which agreed to pay $13.25 million for fraudulently marketing Lidoderm for unapproved use. This, the suit claimed, was an alleged violation of federal and... 
Jan 11, 2018 | Featured Insights
On Dec. 22, 2017, it was announced that whistleblower litigation first filed nearly 10 years ago has finally settled between Kmart Corp., the federal government and several states.The case, US et al. vs. Kmart Corporation, Civil Action No. 12-cv-881-NJR-RJD (SD IL),... 
Oct 19, 2017 | Featured Insights
After suffering several fatalities and overdoses due to prescription opioid abuse, Lackawanna County, Pennsylvania, has retained Marc J. Bern & Partners to lead an action against pharmaceutical companies they believe are responsible for the crisis. The action is...